Xeris Biopharma Holdings (FRA:2B30) Institutional Ownership: 31.92% (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2B30 Xeris Biopharma Holdings Inc FRA:2B30
71 GF Score
Price €7.08
GF Value €4.38
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Institutional Ownership?

Xeris Biopharma Holdings FRA:2B30 -1.99% 71 Institutional Ownership is 31.92% as of Aug. 16, 2026. GuruFocus rates FRA:2B30 with a GF Score™ of 71/100 and a GF Value™ of €4.38 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xeris Biopharma Holdings's institutional ownership is 31.92%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xeris Biopharma Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xeris Biopharma Holdings's Float Percentage Of Total Shares Outstanding is 96.82%.

Xeris Biopharma Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Xeris Biopharma Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Institutional Ownership Chart

Xeris Biopharma Holdings Historical Data

The historical data trend for Xeris Biopharma Holdings can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 30.43 30.46 30.81 30.48 31.04 28.59 29.66 31.09 32.26 31.92
FRA:2B30
71GF Score
Xeris Biopharma Holdings Inc FRA:2B30
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xeris Biopharma Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 31.92% mean?
Xeris Biopharma Holdings (FRA:2B30) has a Institutional Ownership of 31.92% as of Aug. 16, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Institutional Ownership too high?
Xeris Biopharma Holdings' current Institutional Ownership is 31.92%. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Institutional Ownership compare to HROW and PRGO?
Xeris Biopharma Holdings' Institutional Ownership of 31.92% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Institutional Ownership is 31.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (FRA:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.38, compared to a current price of €7.08 — trading 61.6% above its estimated fair value. The current Institutional Ownership is 31.92%. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Xeris Biopharma Holdings (FRA:2B30), the current Institutional Ownership is 31.92% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (FRA:2B30) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of €7.08 is trading 61.6% above its estimated GF Value™ of €4.38. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for FRA:2B30:

  • Institutional Ownership: 31.92%
  • GF Value™: €4.38 vs. price of €7.08 (61.6% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the FRA:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges XERS:USA0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for FRA:2B30

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.08
Price
€4.38
GF Value